P517: SURVIVAL OUTCOMES WITH CPX-351 VS 7 + 3 BY BASELINE BONE MARROW BLAST PERCENTAGE IN OLDER ADULTS WITH NEWLY DIAGNOSED HIGH-RISK OR SECONDARY ACUTE MYELOID LEUKEMIA: A 5-YEAR FOLLOW-UP STUDY
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-08-01
|
| Series: | HemaSphere |
| Online Access: | http://journals.lww.com/10.1097/01.HS9.0000968976.77539.68 |
| _version_ | 1797280122393329664 |
|---|---|
| author | Ellen Ritchie Tara L. Lin Laura F. Newell Robert K. Stuart Scott Solomon Richard Stone Gary Schiller Matthew Wieduwilt Eileen Amy Ryan Nalina Dronamraju Jeffrey Lancet Jorge Cortes |
| author_facet | Ellen Ritchie Tara L. Lin Laura F. Newell Robert K. Stuart Scott Solomon Richard Stone Gary Schiller Matthew Wieduwilt Eileen Amy Ryan Nalina Dronamraju Jeffrey Lancet Jorge Cortes |
| author_sort | Ellen Ritchie |
| collection | DOAJ |
| first_indexed | 2024-03-07T16:36:37Z |
| format | Article |
| id | doaj.art-adfffa9e836c4f858b031d7da2a6b267 |
| institution | Directory Open Access Journal |
| issn | 2572-9241 |
| language | English |
| last_indexed | 2024-03-07T16:36:37Z |
| publishDate | 2023-08-01 |
| publisher | Wiley |
| record_format | Article |
| series | HemaSphere |
| spelling | doaj.art-adfffa9e836c4f858b031d7da2a6b2672024-03-03T09:43:32ZengWileyHemaSphere2572-92412023-08-017e775396810.1097/01.HS9.0000968976.77539.68202308003-00418P517: SURVIVAL OUTCOMES WITH CPX-351 VS 7 + 3 BY BASELINE BONE MARROW BLAST PERCENTAGE IN OLDER ADULTS WITH NEWLY DIAGNOSED HIGH-RISK OR SECONDARY ACUTE MYELOID LEUKEMIA: A 5-YEAR FOLLOW-UP STUDYEllen Ritchie0Tara L. Lin1Laura F. Newell2Robert K. Stuart3Scott Solomon4Richard Stone5Gary Schiller6Matthew Wieduwilt7Eileen Amy Ryan8Nalina Dronamraju9Jeffrey Lancet10Jorge Cortes111 Weill Cornell Medicine, The New York Presbyterian Hospital, New York, NY, United States2 University of Kansas Medical Center, Kansas City, KS, United States3 Division of Hematology and Medical Oncology, Oregon Health & Science University, Portland, OR, United States4 Hollings Cancer Center, Medical University of South Carolina, Charleston, SC, United States5 Northside Hospital Cancer Institute, Atlanta, GA, United States6 Dana-Farber Cancer Institute, Boston, MA, United States7 David Geffen School of Medicine at UCLA, Los Angeles, CA, United States8 Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, NC, United States9 University of Rochester, Rochester, New York, NY, United States10 Jazz Pharmaceuticals, Philadelphia, PA, United States11 H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, United States12 Georgia Cancer Center, Augusta University, Augusta, GA, United Stateshttp://journals.lww.com/10.1097/01.HS9.0000968976.77539.68 |
| spellingShingle | Ellen Ritchie Tara L. Lin Laura F. Newell Robert K. Stuart Scott Solomon Richard Stone Gary Schiller Matthew Wieduwilt Eileen Amy Ryan Nalina Dronamraju Jeffrey Lancet Jorge Cortes P517: SURVIVAL OUTCOMES WITH CPX-351 VS 7 + 3 BY BASELINE BONE MARROW BLAST PERCENTAGE IN OLDER ADULTS WITH NEWLY DIAGNOSED HIGH-RISK OR SECONDARY ACUTE MYELOID LEUKEMIA: A 5-YEAR FOLLOW-UP STUDY HemaSphere |
| title | P517: SURVIVAL OUTCOMES WITH CPX-351 VS 7 + 3 BY BASELINE BONE MARROW BLAST PERCENTAGE IN OLDER ADULTS WITH NEWLY DIAGNOSED HIGH-RISK OR SECONDARY ACUTE MYELOID LEUKEMIA: A 5-YEAR FOLLOW-UP STUDY |
| title_full | P517: SURVIVAL OUTCOMES WITH CPX-351 VS 7 + 3 BY BASELINE BONE MARROW BLAST PERCENTAGE IN OLDER ADULTS WITH NEWLY DIAGNOSED HIGH-RISK OR SECONDARY ACUTE MYELOID LEUKEMIA: A 5-YEAR FOLLOW-UP STUDY |
| title_fullStr | P517: SURVIVAL OUTCOMES WITH CPX-351 VS 7 + 3 BY BASELINE BONE MARROW BLAST PERCENTAGE IN OLDER ADULTS WITH NEWLY DIAGNOSED HIGH-RISK OR SECONDARY ACUTE MYELOID LEUKEMIA: A 5-YEAR FOLLOW-UP STUDY |
| title_full_unstemmed | P517: SURVIVAL OUTCOMES WITH CPX-351 VS 7 + 3 BY BASELINE BONE MARROW BLAST PERCENTAGE IN OLDER ADULTS WITH NEWLY DIAGNOSED HIGH-RISK OR SECONDARY ACUTE MYELOID LEUKEMIA: A 5-YEAR FOLLOW-UP STUDY |
| title_short | P517: SURVIVAL OUTCOMES WITH CPX-351 VS 7 + 3 BY BASELINE BONE MARROW BLAST PERCENTAGE IN OLDER ADULTS WITH NEWLY DIAGNOSED HIGH-RISK OR SECONDARY ACUTE MYELOID LEUKEMIA: A 5-YEAR FOLLOW-UP STUDY |
| title_sort | p517 survival outcomes with cpx 351 vs 7 3 by baseline bone marrow blast percentage in older adults with newly diagnosed high risk or secondary acute myeloid leukemia a 5 year follow up study |
| url | http://journals.lww.com/10.1097/01.HS9.0000968976.77539.68 |
| work_keys_str_mv | AT ellenritchie p517survivaloutcomeswithcpx351vs73bybaselinebonemarrowblastpercentageinolderadultswithnewlydiagnosedhighriskorsecondaryacutemyeloidleukemiaa5yearfollowupstudy AT tarallin p517survivaloutcomeswithcpx351vs73bybaselinebonemarrowblastpercentageinolderadultswithnewlydiagnosedhighriskorsecondaryacutemyeloidleukemiaa5yearfollowupstudy AT laurafnewell p517survivaloutcomeswithcpx351vs73bybaselinebonemarrowblastpercentageinolderadultswithnewlydiagnosedhighriskorsecondaryacutemyeloidleukemiaa5yearfollowupstudy AT robertkstuart p517survivaloutcomeswithcpx351vs73bybaselinebonemarrowblastpercentageinolderadultswithnewlydiagnosedhighriskorsecondaryacutemyeloidleukemiaa5yearfollowupstudy AT scottsolomon p517survivaloutcomeswithcpx351vs73bybaselinebonemarrowblastpercentageinolderadultswithnewlydiagnosedhighriskorsecondaryacutemyeloidleukemiaa5yearfollowupstudy AT richardstone p517survivaloutcomeswithcpx351vs73bybaselinebonemarrowblastpercentageinolderadultswithnewlydiagnosedhighriskorsecondaryacutemyeloidleukemiaa5yearfollowupstudy AT garyschiller p517survivaloutcomeswithcpx351vs73bybaselinebonemarrowblastpercentageinolderadultswithnewlydiagnosedhighriskorsecondaryacutemyeloidleukemiaa5yearfollowupstudy AT matthewwieduwilt p517survivaloutcomeswithcpx351vs73bybaselinebonemarrowblastpercentageinolderadultswithnewlydiagnosedhighriskorsecondaryacutemyeloidleukemiaa5yearfollowupstudy AT eileenamyryan p517survivaloutcomeswithcpx351vs73bybaselinebonemarrowblastpercentageinolderadultswithnewlydiagnosedhighriskorsecondaryacutemyeloidleukemiaa5yearfollowupstudy AT nalinadronamraju p517survivaloutcomeswithcpx351vs73bybaselinebonemarrowblastpercentageinolderadultswithnewlydiagnosedhighriskorsecondaryacutemyeloidleukemiaa5yearfollowupstudy AT jeffreylancet p517survivaloutcomeswithcpx351vs73bybaselinebonemarrowblastpercentageinolderadultswithnewlydiagnosedhighriskorsecondaryacutemyeloidleukemiaa5yearfollowupstudy AT jorgecortes p517survivaloutcomeswithcpx351vs73bybaselinebonemarrowblastpercentageinolderadultswithnewlydiagnosedhighriskorsecondaryacutemyeloidleukemiaa5yearfollowupstudy |